MY197627A - Methods for treating and preventing c. difficile infection - Google Patents

Methods for treating and preventing c. difficile infection

Info

Publication number
MY197627A
MY197627A MYPI2018001628A MYPI2018001628A MY197627A MY 197627 A MY197627 A MY 197627A MY PI2018001628 A MYPI2018001628 A MY PI2018001628A MY PI2018001628 A MYPI2018001628 A MY PI2018001628A MY 197627 A MY197627 A MY 197627A
Authority
MY
Malaysia
Prior art keywords
treating
preventing
methods
difficile infection
difficile
Prior art date
Application number
MYPI2018001628A
Other languages
English (en)
Inventor
S Ken Tanaka
Michael P Draper
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of MY197627A publication Critical patent/MY197627A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
MYPI2018001628A 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection MY197627A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US201662320053P 2016-04-08 2016-04-08
PCT/US2017/023958 WO2017165729A1 (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Publications (1)

Publication Number Publication Date
MY197627A true MY197627A (en) 2023-06-29

Family

ID=59900751

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018001628A MY197627A (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Country Status (13)

Country Link
US (3) US20170319603A1 (cg-RX-API-DMAC7.html)
EP (1) EP3432891A4 (cg-RX-API-DMAC7.html)
JP (3) JP7458706B2 (cg-RX-API-DMAC7.html)
CN (2) CN119454720A (cg-RX-API-DMAC7.html)
AU (3) AU2017238644B2 (cg-RX-API-DMAC7.html)
BR (2) BR122024000249A2 (cg-RX-API-DMAC7.html)
CA (1) CA3018872A1 (cg-RX-API-DMAC7.html)
MX (2) MX2018011413A (cg-RX-API-DMAC7.html)
MY (1) MY197627A (cg-RX-API-DMAC7.html)
PH (1) PH12018502020A1 (cg-RX-API-DMAC7.html)
RU (1) RU2751509C1 (cg-RX-API-DMAC7.html)
SG (2) SG11201808246SA (cg-RX-API-DMAC7.html)
WO (1) WO2017165729A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122024000249A2 (pt) * 2016-03-24 2024-02-27 Paratek Pharmaceuticals, Inc. Uso de um composto ou um sal do mesmo
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
MY200446A (en) * 2016-11-01 2023-12-26 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
CN113164456A (zh) * 2018-09-04 2021-07-23 帕拉特克药品公司 使用四环素化合物治疗分枝杆菌感染的方法
CA3113221A1 (en) * 2018-10-10 2020-04-16 Nutri Co., Ltd. Preventive and/or therapeutic agent for clostridium difficile infection
CA3179596A1 (en) * 2020-06-11 2021-12-16 Tadeusz Warchol Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509340A (ja) * 1991-07-24 1994-10-20 ザ、プロクター、エンド、ギャンブル、カンパニー 抗菌治療方法及び組成物
CN1690047B (zh) * 2000-07-07 2010-10-06 塔夫茨大学信托人 9-取代的二甲胺四环素化合物
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP2332547A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of inflammatory bowel disease
RU2008121238A (ru) * 2005-12-22 2010-01-27 Вайет (Us) Способы лечения инфекций желудочно-кишечного тракта с применением тайгециклина
AU2007208214B2 (en) * 2006-01-24 2013-02-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
TW202436282A (zh) * 2008-05-19 2024-09-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
CA2752020A1 (en) * 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
JP5965389B2 (ja) * 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
EP2956006A4 (en) * 2013-02-04 2017-02-22 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
BR122024000249A2 (pt) * 2016-03-24 2024-02-27 Paratek Pharmaceuticals, Inc. Uso de um composto ou um sal do mesmo

Also Published As

Publication number Publication date
US20250049819A1 (en) 2025-02-13
US20200281948A1 (en) 2020-09-10
PH12018502020A1 (en) 2019-07-15
SG11201808246SA (en) 2018-10-30
SG10201913559VA (en) 2020-02-27
EP3432891A1 (en) 2019-01-30
US20170319603A1 (en) 2017-11-09
MX2023004969A (es) 2023-05-24
RU2751509C1 (ru) 2021-07-14
JP7458706B2 (ja) 2024-04-01
MX2018011413A (es) 2019-01-10
AU2025202020A1 (en) 2025-04-10
AU2023200798A1 (en) 2023-03-09
JP2019509318A (ja) 2019-04-04
BR122024000249A2 (pt) 2024-02-27
WO2017165729A1 (en) 2017-09-28
EP3432891A4 (en) 2019-10-30
BR112018069303A2 (pt) 2019-01-22
JP2024023187A (ja) 2024-02-21
AU2017238644B2 (en) 2022-12-15
AU2017238644A1 (en) 2018-10-25
CA3018872A1 (en) 2017-09-28
CN119454720A (zh) 2025-02-18
JP2022115985A (ja) 2022-08-09
CN109152789A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
MY197627A (en) Methods for treating and preventing c. difficile infection
SA519402400B1 (ar) تركيبات وطرق لعلاج أمراض الهيموجلوبين
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2019003938A (es) Compuestos espirociclicos.
MX2018003472A (es) Moduladores de la expresion de kras.
MX2021010418A (es) Composiciones que comprenden una caseína y métodos para producir las mismas.
GB2541571A (en) Pharmaceutical compositions
WO2015117081A3 (en) Methods and compositions for treatment of a beta thalessemia
EP3538189A4 (en) COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF CONDITIONS MEDIATED BY AN OPIOID RECEPTOR
MX2022006768A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
EA201991818A1 (ru) Лечение рака
SG11201811429XA (en) Flow reactor
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
EP4286005A3 (en) Cancer treatment
MX379622B (es) Compuestos espirociclicos
WO2017096303A3 (en) Cerdulatinib for treating hematological cancers
PH12017500602A1 (en) Methods for treating ocular conditions
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EP4480577A3 (en) Structured elements and methods of use